Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2018-04

AUTHORS

J. N. Jakobsen, T. Urup, K. Grunnet, A. Toft, M. D. Johansen, S. H. Poulsen, I. J. Christensen, A. Muhic, H. S. Poulsen

ABSTRACT

The combination of lomustine and bevacizumab is a commonly used salvage treatment for recurrent glioblastoma (GBM). We investigated the toxicity and efficacy of lomustine plus bevacizumab (lom-bev) in a community-based patient cohort and made a comparison to another frequently used combination therapy consisting of irinotecan plus bevacizumab (iri-bev). Seventy patients with recurrent GBM were treated with lomustine 90 mg/m2 every 6 weeks and bevacizumab 10 mg/kg every 2 weeks. Toxicity was registered and compared to the toxicity observed in 219 recurrent GBM patients who had previously been treated with irinotecan 125 mg/m2 and bevacizumab 10 mg/kg every 2 weeks. The response rate was 37.1% for lom-bev and 30.1% for iri-bev. Median progression-free survival (PFS) was 23 weeks for lom-bev and 21 weeks for iri-bev (p = 0.9). Overall survival (OS) was 37 weeks for lom-bev and 32 weeks for iri-bev (p = 0.5). Lom-bev caused a significantly higher frequency of thrombocytopenia (11.4% grade 3-4) compared to iri-bev (3.5% grade 3-4). Iri-bev patients had more gastrointestinal toxicity with regard to nausea, vomiting, diarrhea, constipation and stomatitis. Within the limitations of the study lom-bev is a well-tolerated treatment for recurrent GBM, although hematological toxicity may be a dose limiting factor. No significant differences between lom-bev and iri-bev were observed with regard to PFS or OS. The differences in toxicity profiles between lom-bev and iri-bev could guide treatment decision in recurrent GBM therapy as efficacy is equal and no predictive factors for efficacy exist. More... »

PAGES

439-446

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11060-017-2736-x

DOI

http://dx.doi.org/10.1007/s11060-017-2736-x

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1100349040

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29330749


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents, Immunological", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bevacizumab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Brain Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glioblastoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Irinotecan", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lomustine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Recurrence, Local", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Salvage Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Rigshospitalet", 
          "id": "https://www.grid.ac/institutes/grid.475435.4", 
          "name": [
            "Department of Oncology, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jakobsen", 
        "givenName": "J. N.", 
        "id": "sg:person.01213020261.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01213020261.76"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Rigshospitalet", 
          "id": "https://www.grid.ac/institutes/grid.475435.4", 
          "name": [
            "Department of Oncology, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Urup", 
        "givenName": "T.", 
        "id": "sg:person.0767755164.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0767755164.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Rigshospitalet", 
          "id": "https://www.grid.ac/institutes/grid.475435.4", 
          "name": [
            "Department of Radiation Biology, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Grunnet", 
        "givenName": "K.", 
        "id": "sg:person.0625037311.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0625037311.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Rigshospitalet", 
          "id": "https://www.grid.ac/institutes/grid.475435.4", 
          "name": [
            "Department of Radiation Biology, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Toft", 
        "givenName": "A.", 
        "id": "sg:person.01355370407.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01355370407.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Rigshospitalet", 
          "id": "https://www.grid.ac/institutes/grid.475435.4", 
          "name": [
            "Department of Radiation Biology, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Johansen", 
        "givenName": "M. D.", 
        "id": "sg:person.01030124627.78", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01030124627.78"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Rigshospitalet", 
          "id": "https://www.grid.ac/institutes/grid.475435.4", 
          "name": [
            "Department of Oncology, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark", 
            "Department of Radiation Biology, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Poulsen", 
        "givenName": "S. H.", 
        "id": "sg:person.016546037435.99", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016546037435.99"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hvidovre Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411905.8", 
          "name": [
            "Department of Surgical Gastroenterology, Hvidovre Hospital, Ketteg\u00e5rds Alle 30, Hvidovre, Denmark"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Christensen", 
        "givenName": "I. J.", 
        "id": "sg:person.011624566757.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011624566757.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Rigshospitalet", 
          "id": "https://www.grid.ac/institutes/grid.475435.4", 
          "name": [
            "Department of Oncology, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Muhic", 
        "givenName": "A.", 
        "id": "sg:person.0655460655.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0655460655.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Rigshospitalet", 
          "id": "https://www.grid.ac/institutes/grid.475435.4", 
          "name": [
            "Department of Radiation Biology, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Poulsen", 
        "givenName": "H. S.", 
        "id": "sg:person.01226567303.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01226567303.29"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1517/14656566.2011.566558", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003393613"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/neuonc/not226", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012339161"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.molonc.2016.05.005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025103697"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3109/0284186x.2012.681063", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026913192"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/02841860802537924", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033303184"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3109/0284186x.2015.1114679", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036696795"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1159/000085575", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041501068"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.19.8721", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042965400"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2009.26.3541", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043187529"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(14)70314-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044429820"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11060-011-0565-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046283234", 
          "https://doi.org/10.1007/s11060-011-0565-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa043330", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052112015"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-14-3040", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1063224826"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1990.8.7.1277", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1078716995"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1707358", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092706366"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-04", 
    "datePublishedReg": "2018-04-01", 
    "description": "The combination of lomustine and bevacizumab is a commonly used salvage treatment for recurrent glioblastoma (GBM). We investigated the toxicity and efficacy of lomustine plus bevacizumab (lom-bev) in a community-based patient cohort and made a comparison to another frequently used combination therapy consisting of irinotecan plus bevacizumab (iri-bev). Seventy patients with recurrent GBM were treated with lomustine 90\u00a0mg/m2 every 6 weeks and bevacizumab 10\u00a0mg/kg every 2 weeks. Toxicity was registered and compared to the toxicity observed in 219 recurrent GBM patients who had previously been treated with irinotecan 125\u00a0mg/m2 and bevacizumab 10\u00a0mg/kg every 2 weeks. The response rate was 37.1% for lom-bev and 30.1% for iri-bev. Median progression-free survival (PFS) was 23 weeks for lom-bev and 21 weeks for iri-bev (p\u2009=\u20090.9). Overall survival (OS) was 37 weeks for lom-bev and 32 weeks for iri-bev (p\u2009=\u20090.5). Lom-bev caused a significantly higher frequency of thrombocytopenia (11.4% grade 3-4) compared to iri-bev (3.5% grade 3-4). Iri-bev patients had more gastrointestinal toxicity with regard to nausea, vomiting, diarrhea, constipation and stomatitis. Within the limitations of the study lom-bev is a well-tolerated treatment for recurrent GBM, although hematological toxicity may be a dose limiting factor. No significant differences between lom-bev and iri-bev were observed with regard to PFS or OS. The differences in toxicity profiles between lom-bev and iri-bev could guide treatment decision in recurrent GBM therapy as efficacy is equal and no predictive factors for efficacy exist.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s11060-017-2736-x", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094205", 
        "issn": [
          "0167-594X", 
          "1573-7373"
        ], 
        "name": "Journal of Neuro-Oncology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "137"
      }
    ], 
    "name": "Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients", 
    "pagination": "439-446", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "1e3ff22d90422d1a26c8609deb615365a16edbcb3c4c48d40a4d653f9d9900e1"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29330749"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8309335"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11060-017-2736-x"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1100349040"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11060-017-2736-x", 
      "https://app.dimensions.ai/details/publication/pub.1100349040"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T09:40", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000346_0000000346/records_99839_00000004.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs11060-017-2736-x"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11060-017-2736-x'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11060-017-2736-x'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11060-017-2736-x'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11060-017-2736-x'


 

This table displays all metadata directly associated to this object as RDF triples.

247 TRIPLES      21 PREDICATES      62 URIs      39 LITERALS      27 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11060-017-2736-x schema:about N1c31f738961343aaa424b2ec0dbb7b06
2 N23bd7f0aa6de423fabf8c21c8ae77eb9
3 N273800e08eb64809b00eb76fd8cf0614
4 N2943e584ce694fef8b4ac5d5da9c8bad
5 N3be253f01c2b42ff986be792d87f1b97
6 N56aa1ab93fc04661bd39dcdc55f210f7
7 N5815fe16b85b430796bdec6def711807
8 N65ca6db082bd4165b10e0252be02d390
9 N79eb0b89252b4329a3d7cab6e194be34
10 N8f0d23fc0b6647c4b9b926c8011469d7
11 N9460729f64e94c498464517538a2ea2e
12 N996c0d9bbce940288526ca6739a23020
13 Nc6a720a2afd94ac2b80c0d9091fd7aab
14 Nd2f14b138e174e519b4afe5da08a64e6
15 Nd36e001fd5fe4cf29afcc2b5b9c98957
16 Ne5b875eac2114bb78d84fa539d703333
17 Ne73d032abc0040d19262807ba8930860
18 Nebb3d49d46284e71a003c24222a3a22a
19 anzsrc-for:11
20 anzsrc-for:1103
21 schema:author Ndee4ee742bcf464d9c81d4cefbae8258
22 schema:citation sg:pub.10.1007/s11060-011-0565-x
23 https://doi.org/10.1016/j.molonc.2016.05.005
24 https://doi.org/10.1016/s1470-2045(14)70314-6
25 https://doi.org/10.1056/nejmoa043330
26 https://doi.org/10.1056/nejmoa1707358
27 https://doi.org/10.1080/02841860802537924
28 https://doi.org/10.1093/neuonc/not226
29 https://doi.org/10.1158/1078-0432.ccr-14-3040
30 https://doi.org/10.1159/000085575
31 https://doi.org/10.1200/jco.1990.8.7.1277
32 https://doi.org/10.1200/jco.2008.19.8721
33 https://doi.org/10.1200/jco.2009.26.3541
34 https://doi.org/10.1517/14656566.2011.566558
35 https://doi.org/10.3109/0284186x.2012.681063
36 https://doi.org/10.3109/0284186x.2015.1114679
37 schema:datePublished 2018-04
38 schema:datePublishedReg 2018-04-01
39 schema:description The combination of lomustine and bevacizumab is a commonly used salvage treatment for recurrent glioblastoma (GBM). We investigated the toxicity and efficacy of lomustine plus bevacizumab (lom-bev) in a community-based patient cohort and made a comparison to another frequently used combination therapy consisting of irinotecan plus bevacizumab (iri-bev). Seventy patients with recurrent GBM were treated with lomustine 90 mg/m<sup>2</sup> every 6 weeks and bevacizumab 10 mg/kg every 2 weeks. Toxicity was registered and compared to the toxicity observed in 219 recurrent GBM patients who had previously been treated with irinotecan 125 mg/m<sup>2</sup> and bevacizumab 10 mg/kg every 2 weeks. The response rate was 37.1% for lom-bev and 30.1% for iri-bev. Median progression-free survival (PFS) was 23 weeks for lom-bev and 21 weeks for iri-bev (p = 0.9). Overall survival (OS) was 37 weeks for lom-bev and 32 weeks for iri-bev (p = 0.5). Lom-bev caused a significantly higher frequency of thrombocytopenia (11.4% grade 3-4) compared to iri-bev (3.5% grade 3-4). Iri-bev patients had more gastrointestinal toxicity with regard to nausea, vomiting, diarrhea, constipation and stomatitis. Within the limitations of the study lom-bev is a well-tolerated treatment for recurrent GBM, although hematological toxicity may be a dose limiting factor. No significant differences between lom-bev and iri-bev were observed with regard to PFS or OS. The differences in toxicity profiles between lom-bev and iri-bev could guide treatment decision in recurrent GBM therapy as efficacy is equal and no predictive factors for efficacy exist.
40 schema:genre research_article
41 schema:inLanguage en
42 schema:isAccessibleForFree false
43 schema:isPartOf N015cc94b8e0c43fa8da2f8f60b41a897
44 N11d241d06cce46ebb42ad566704b5c6f
45 sg:journal.1094205
46 schema:name Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients
47 schema:pagination 439-446
48 schema:productId N06d7df19bc5e4172a365e3a8280aed55
49 N0e3ea791e525454b8182795cca1d9bd1
50 N4466692a9cf6400e9d4152f177bbfdfb
51 N5cc858b625e44862bb7e33ab4d012a3f
52 N70c8b1508402429b894920e7127d6e97
53 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100349040
54 https://doi.org/10.1007/s11060-017-2736-x
55 schema:sdDatePublished 2019-04-11T09:40
56 schema:sdLicense https://scigraph.springernature.com/explorer/license/
57 schema:sdPublisher Nbd77faf4f2b94648b8ef8981c880a125
58 schema:url https://link.springer.com/10.1007%2Fs11060-017-2736-x
59 sgo:license sg:explorer/license/
60 sgo:sdDataset articles
61 rdf:type schema:ScholarlyArticle
62 N015cc94b8e0c43fa8da2f8f60b41a897 schema:issueNumber 2
63 rdf:type schema:PublicationIssue
64 N06d7df19bc5e4172a365e3a8280aed55 schema:name pubmed_id
65 schema:value 29330749
66 rdf:type schema:PropertyValue
67 N0e3ea791e525454b8182795cca1d9bd1 schema:name readcube_id
68 schema:value 1e3ff22d90422d1a26c8609deb615365a16edbcb3c4c48d40a4d653f9d9900e1
69 rdf:type schema:PropertyValue
70 N11d241d06cce46ebb42ad566704b5c6f schema:volumeNumber 137
71 rdf:type schema:PublicationVolume
72 N1a48b287377342a2906ed3573e48bba0 rdf:first sg:person.01355370407.00
73 rdf:rest N559824b574384bd2a8f7dcc035b97f28
74 N1c31f738961343aaa424b2ec0dbb7b06 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
75 schema:name Brain Neoplasms
76 rdf:type schema:DefinedTerm
77 N23bd7f0aa6de423fabf8c21c8ae77eb9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
78 schema:name Male
79 rdf:type schema:DefinedTerm
80 N273800e08eb64809b00eb76fd8cf0614 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
81 schema:name Antineoplastic Combined Chemotherapy Protocols
82 rdf:type schema:DefinedTerm
83 N2943e584ce694fef8b4ac5d5da9c8bad schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
84 schema:name Neoplasm Recurrence, Local
85 rdf:type schema:DefinedTerm
86 N3be253f01c2b42ff986be792d87f1b97 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
87 schema:name Irinotecan
88 rdf:type schema:DefinedTerm
89 N3fc8227b15074d5a9a8249f07288ae73 rdf:first sg:person.016546037435.99
90 rdf:rest Ndce6c029fe20480383925ddebd41946f
91 N4466692a9cf6400e9d4152f177bbfdfb schema:name dimensions_id
92 schema:value pub.1100349040
93 rdf:type schema:PropertyValue
94 N559824b574384bd2a8f7dcc035b97f28 rdf:first sg:person.01030124627.78
95 rdf:rest N3fc8227b15074d5a9a8249f07288ae73
96 N56aa1ab93fc04661bd39dcdc55f210f7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Adult
98 rdf:type schema:DefinedTerm
99 N5815fe16b85b430796bdec6def711807 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Follow-Up Studies
101 rdf:type schema:DefinedTerm
102 N5cc858b625e44862bb7e33ab4d012a3f schema:name nlm_unique_id
103 schema:value 8309335
104 rdf:type schema:PropertyValue
105 N65ca6db082bd4165b10e0252be02d390 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Antineoplastic Agents, Immunological
107 rdf:type schema:DefinedTerm
108 N70c8b1508402429b894920e7127d6e97 schema:name doi
109 schema:value 10.1007/s11060-017-2736-x
110 rdf:type schema:PropertyValue
111 N79eb0b89252b4329a3d7cab6e194be34 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Salvage Therapy
113 rdf:type schema:DefinedTerm
114 N8ba9f28b7d10423bad052f522882818d rdf:first sg:person.0625037311.06
115 rdf:rest N1a48b287377342a2906ed3573e48bba0
116 N8f0d23fc0b6647c4b9b926c8011469d7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Young Adult
118 rdf:type schema:DefinedTerm
119 N9460729f64e94c498464517538a2ea2e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Treatment Outcome
121 rdf:type schema:DefinedTerm
122 N996c0d9bbce940288526ca6739a23020 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Middle Aged
124 rdf:type schema:DefinedTerm
125 N9f436a60833a42f4a5cb184f7da885b5 rdf:first sg:person.0655460655.30
126 rdf:rest Na97292bda7b44892ba9c18ac6aa720a6
127 Na97292bda7b44892ba9c18ac6aa720a6 rdf:first sg:person.01226567303.29
128 rdf:rest rdf:nil
129 Nbd77faf4f2b94648b8ef8981c880a125 schema:name Springer Nature - SN SciGraph project
130 rdf:type schema:Organization
131 Nc2730c27d2634804b59ac688eaed381d rdf:first sg:person.0767755164.36
132 rdf:rest N8ba9f28b7d10423bad052f522882818d
133 Nc6a720a2afd94ac2b80c0d9091fd7aab schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Lomustine
135 rdf:type schema:DefinedTerm
136 Nd2f14b138e174e519b4afe5da08a64e6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Humans
138 rdf:type schema:DefinedTerm
139 Nd36e001fd5fe4cf29afcc2b5b9c98957 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Female
141 rdf:type schema:DefinedTerm
142 Ndce6c029fe20480383925ddebd41946f rdf:first sg:person.011624566757.20
143 rdf:rest N9f436a60833a42f4a5cb184f7da885b5
144 Ndee4ee742bcf464d9c81d4cefbae8258 rdf:first sg:person.01213020261.76
145 rdf:rest Nc2730c27d2634804b59ac688eaed381d
146 Ne5b875eac2114bb78d84fa539d703333 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Aged
148 rdf:type schema:DefinedTerm
149 Ne73d032abc0040d19262807ba8930860 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Bevacizumab
151 rdf:type schema:DefinedTerm
152 Nebb3d49d46284e71a003c24222a3a22a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Glioblastoma
154 rdf:type schema:DefinedTerm
155 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
156 schema:name Medical and Health Sciences
157 rdf:type schema:DefinedTerm
158 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
159 schema:name Clinical Sciences
160 rdf:type schema:DefinedTerm
161 sg:journal.1094205 schema:issn 0167-594X
162 1573-7373
163 schema:name Journal of Neuro-Oncology
164 rdf:type schema:Periodical
165 sg:person.01030124627.78 schema:affiliation https://www.grid.ac/institutes/grid.475435.4
166 schema:familyName Johansen
167 schema:givenName M. D.
168 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01030124627.78
169 rdf:type schema:Person
170 sg:person.011624566757.20 schema:affiliation https://www.grid.ac/institutes/grid.411905.8
171 schema:familyName Christensen
172 schema:givenName I. J.
173 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011624566757.20
174 rdf:type schema:Person
175 sg:person.01213020261.76 schema:affiliation https://www.grid.ac/institutes/grid.475435.4
176 schema:familyName Jakobsen
177 schema:givenName J. N.
178 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01213020261.76
179 rdf:type schema:Person
180 sg:person.01226567303.29 schema:affiliation https://www.grid.ac/institutes/grid.475435.4
181 schema:familyName Poulsen
182 schema:givenName H. S.
183 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01226567303.29
184 rdf:type schema:Person
185 sg:person.01355370407.00 schema:affiliation https://www.grid.ac/institutes/grid.475435.4
186 schema:familyName Toft
187 schema:givenName A.
188 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01355370407.00
189 rdf:type schema:Person
190 sg:person.016546037435.99 schema:affiliation https://www.grid.ac/institutes/grid.475435.4
191 schema:familyName Poulsen
192 schema:givenName S. H.
193 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016546037435.99
194 rdf:type schema:Person
195 sg:person.0625037311.06 schema:affiliation https://www.grid.ac/institutes/grid.475435.4
196 schema:familyName Grunnet
197 schema:givenName K.
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0625037311.06
199 rdf:type schema:Person
200 sg:person.0655460655.30 schema:affiliation https://www.grid.ac/institutes/grid.475435.4
201 schema:familyName Muhic
202 schema:givenName A.
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0655460655.30
204 rdf:type schema:Person
205 sg:person.0767755164.36 schema:affiliation https://www.grid.ac/institutes/grid.475435.4
206 schema:familyName Urup
207 schema:givenName T.
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0767755164.36
209 rdf:type schema:Person
210 sg:pub.10.1007/s11060-011-0565-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1046283234
211 https://doi.org/10.1007/s11060-011-0565-x
212 rdf:type schema:CreativeWork
213 https://doi.org/10.1016/j.molonc.2016.05.005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025103697
214 rdf:type schema:CreativeWork
215 https://doi.org/10.1016/s1470-2045(14)70314-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044429820
216 rdf:type schema:CreativeWork
217 https://doi.org/10.1056/nejmoa043330 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052112015
218 rdf:type schema:CreativeWork
219 https://doi.org/10.1056/nejmoa1707358 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092706366
220 rdf:type schema:CreativeWork
221 https://doi.org/10.1080/02841860802537924 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033303184
222 rdf:type schema:CreativeWork
223 https://doi.org/10.1093/neuonc/not226 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012339161
224 rdf:type schema:CreativeWork
225 https://doi.org/10.1158/1078-0432.ccr-14-3040 schema:sameAs https://app.dimensions.ai/details/publication/pub.1063224826
226 rdf:type schema:CreativeWork
227 https://doi.org/10.1159/000085575 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041501068
228 rdf:type schema:CreativeWork
229 https://doi.org/10.1200/jco.1990.8.7.1277 schema:sameAs https://app.dimensions.ai/details/publication/pub.1078716995
230 rdf:type schema:CreativeWork
231 https://doi.org/10.1200/jco.2008.19.8721 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042965400
232 rdf:type schema:CreativeWork
233 https://doi.org/10.1200/jco.2009.26.3541 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043187529
234 rdf:type schema:CreativeWork
235 https://doi.org/10.1517/14656566.2011.566558 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003393613
236 rdf:type schema:CreativeWork
237 https://doi.org/10.3109/0284186x.2012.681063 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026913192
238 rdf:type schema:CreativeWork
239 https://doi.org/10.3109/0284186x.2015.1114679 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036696795
240 rdf:type schema:CreativeWork
241 https://www.grid.ac/institutes/grid.411905.8 schema:alternateName Hvidovre Hospital
242 schema:name Department of Surgical Gastroenterology, Hvidovre Hospital, Kettegårds Alle 30, Hvidovre, Denmark
243 rdf:type schema:Organization
244 https://www.grid.ac/institutes/grid.475435.4 schema:alternateName Rigshospitalet
245 schema:name Department of Oncology, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark
246 Department of Radiation Biology, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark
247 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...